ES2749651T3 - Método basado en microARN para la detección temprana de cáncer de próstata en muestras de orina - Google Patents
Método basado en microARN para la detección temprana de cáncer de próstata en muestras de orina Download PDFInfo
- Publication number
- ES2749651T3 ES2749651T3 ES16706303T ES16706303T ES2749651T3 ES 2749651 T3 ES2749651 T3 ES 2749651T3 ES 16706303 T ES16706303 T ES 16706303T ES 16706303 T ES16706303 T ES 16706303T ES 2749651 T3 ES2749651 T3 ES 2749651T3
- Authority
- ES
- Spain
- Prior art keywords
- mir
- hsa
- expression
- level
- diagnostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500079 | 2015-02-11 | ||
| DKPA201500825 | 2015-12-21 | ||
| PCT/DK2016/050032 WO2016127998A1 (en) | 2015-02-11 | 2016-02-05 | A microrna-based method for early detection of prostate cancer in urine samples |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2749651T3 true ES2749651T3 (es) | 2020-03-23 |
Family
ID=55435920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16706303T Active ES2749651T3 (es) | 2015-02-11 | 2016-02-05 | Método basado en microARN para la detección temprana de cáncer de próstata en muestras de orina |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10400288B2 (enExample) |
| EP (1) | EP3256602B1 (enExample) |
| JP (1) | JP2018504915A (enExample) |
| CA (1) | CA2976577C (enExample) |
| ES (1) | ES2749651T3 (enExample) |
| WO (1) | WO2016127998A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2977439C (en) | 2015-02-27 | 2025-05-20 | Aarhus Universitet | MICRORNA-BASED METHOD FOR EVALUATING THE PROGNOSIS OF A PATIENT WITH PROSTATE CANCER |
| WO2018049506A1 (en) * | 2016-09-14 | 2018-03-22 | Ontario Institute For Cancer Research (Oicr) | Mirna prostate cancer marker |
| CN106834470A (zh) * | 2017-02-17 | 2017-06-13 | 张灏 | miRNA在制备癌症诊断试剂盒中的用途 |
| WO2018159750A1 (ja) * | 2017-03-02 | 2018-09-07 | 第一三共株式会社 | オピオイド薬の治療有効性を予測するためのｍｉｃｒｏＲＮＡバイオマーカー |
| CN107488734B (zh) * | 2017-10-10 | 2019-11-05 | 广州医科大学附属第二医院 | miR-19a-3p在制备前列腺癌骨转移诊断试剂和治疗药物中的应用 |
| CN107663541A (zh) * | 2017-10-31 | 2018-02-06 | 温州医科大学 | 一种用于诊断原发性肝癌的特异性生物标志物及其筛选方法与应用 |
| US20210147944A1 (en) * | 2018-04-10 | 2021-05-20 | Unity Health Toronto | Methods for monitoring and treating prostate cancer |
| WO2019220759A1 (ja) * | 2018-05-17 | 2019-11-21 | Ｓｔｅｍｃｅｌｌ株式会社 | がんの分析方法、がんの分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体 |
| CN108424962B (zh) * | 2018-05-25 | 2021-08-03 | 中国人民解放军陆军军医大学 | 系膜增生性肾小球肾炎的miRNA检测标志物及其诊断试剂盒 |
| CN109112109A (zh) * | 2018-07-27 | 2019-01-01 | 浙江大学 | 一种骨髓间充质干细胞外泌体的改造方法 |
| EP3699300A1 (en) * | 2019-02-22 | 2020-08-26 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Seminal mirnas as non-invasive biomarkers for the diagnosis and/or prognosis of prostate cancer |
| WO2020190819A1 (en) | 2019-03-15 | 2020-09-24 | Mir Scientific, Llc | Methods for predicting prostate cancer and uses thereof |
| EP3719144A1 (en) * | 2019-04-05 | 2020-10-07 | Fundación para la Investigación Biomédica del Hospital Universitario de la Paz (FIBHULP) | Mir-151a-3p as an universal endogenous control for exosome cargo normalization |
| JP2020195314A (ja) * | 2019-05-31 | 2020-12-10 | 医薬資源研究所株式会社 | 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体 |
| EP4029940A4 (en) * | 2019-09-09 | 2024-02-28 | Craif Inc. | Body fluid extract containing micro rna |
| CN111118165B (zh) * | 2020-03-04 | 2023-04-07 | 朱伟 | 一种与前列腺癌辅助诊断相关的血清miRNA标志物及其应用 |
| CN112094910B (zh) * | 2020-09-25 | 2023-03-24 | 无锡市中医医院 | 一种用于前列腺癌患病风险评估的miRNA标志物 |
| CN112795657A (zh) * | 2021-03-22 | 2021-05-14 | 中国农业大学 | miRNA在制备诊断或辅助诊断哺乳动物前列腺癌症产品中的应用 |
| WO2022209943A1 (ja) * | 2021-03-29 | 2022-10-06 | 東レ株式会社 | 生体試料中のマイクロｒｎａの検出方法、中性アミノ酸の塩酸塩の組成物および容器 |
| KR102550113B1 (ko) * | 2021-05-28 | 2023-07-03 | 주식회사 시스바이오젠 | 전립선암 진단용 바이오마커 및 이의 용도 |
| JP2023018634A (ja) * | 2021-07-27 | 2023-02-08 | 東レ株式会社 | 生体試料中のマイクロｒｎａの検出方法、中性アミノ酸の塩酸塩の組成物および容器 |
| CN114045344B (zh) * | 2021-12-09 | 2024-12-17 | 觅瑞（杭州）生物科技有限公司 | 前列腺癌诊断用尿液miRNA标志物、诊断试剂及试剂盒 |
| ES2995178A1 (es) * | 2023-07-31 | 2025-02-07 | Servicio Andaluz De Salud | Biomarcadores y método de diagnóstico de la diabetes monogénica en adultos jóvenes portadores de alelos HNF1A deletéreos |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0816852A2 (pt) | 2007-09-14 | 2017-06-06 | Univ Ohio State Res Found | método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer. |
| EP2634266B1 (en) * | 2009-05-22 | 2015-10-14 | Asuragen, INC. | miRNA biomarkers of prostate disease |
| WO2011057003A2 (en) | 2009-11-04 | 2011-05-12 | Samuil Umansky | Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases |
| EP2341145A1 (en) * | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| CA3081061C (en) | 2010-07-27 | 2023-01-03 | Genomic Health, Inc. | Method for using expression of klk2 to determine prognosis of prostate cancer |
| WO2013063544A1 (en) | 2011-10-27 | 2013-05-02 | Asuragen, Inc. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
| US9944991B2 (en) | 2012-11-02 | 2018-04-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies |
| WO2014085906A1 (en) | 2012-12-03 | 2014-06-12 | St. Michael's Hospital | Microrna biomarkers for prostate cancer |
| CA2834187A1 (en) * | 2013-04-15 | 2014-10-15 | Norgen Biotek Corporation | Use of micrornas for screening and diagnosis of prostate cancer and benign prostatic hyperplasia |
| CN103882118A (zh) * | 2014-02-13 | 2014-06-25 | 绍兴市人民医院 | 用于检测前列腺癌的miRNAs |
| CN111996254B (zh) * | 2014-06-12 | 2024-10-18 | 东丽株式会社 | 前列腺癌的检测试剂盒或装置以及检测方法 |
| EP3000895A1 (en) | 2014-09-26 | 2016-03-30 | Integragen | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| WO2016115312A1 (en) * | 2015-01-14 | 2016-07-21 | Ohio State Innovation Foundation | Mirna-based predictive models for diagnosis and prognosis of prostate cancer |
| CA2977439C (en) | 2015-02-27 | 2025-05-20 | Aarhus Universitet | MICRORNA-BASED METHOD FOR EVALUATING THE PROGNOSIS OF A PATIENT WITH PROSTATE CANCER |
-
2016
- 2016-02-05 US US15/550,416 patent/US10400288B2/en active Active
- 2016-02-05 WO PCT/DK2016/050032 patent/WO2016127998A1/en not_active Ceased
- 2016-02-05 EP EP16706303.1A patent/EP3256602B1/en active Active
- 2016-02-05 JP JP2017541256A patent/JP2018504915A/ja active Pending
- 2016-02-05 CA CA2976577A patent/CA2976577C/en active Active
- 2016-02-05 ES ES16706303T patent/ES2749651T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2976577C (en) | 2024-11-19 |
| US10400288B2 (en) | 2019-09-03 |
| CA2976577A1 (en) | 2016-08-18 |
| EP3256602A1 (en) | 2017-12-20 |
| JP2018504915A (ja) | 2018-02-22 |
| US20180030542A1 (en) | 2018-02-01 |
| WO2016127998A1 (en) | 2016-08-18 |
| EP3256602B1 (en) | 2019-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10400288B2 (en) | MicroRNA-based method for early detection of prostate cancer in urine samples | |
| Leite et al. | Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer | |
| US20100178653A1 (en) | Gene expression signature for classification of cancers | |
| JP6216470B2 (ja) | 甲状腺腫瘍の分類におけるｍｉＲＮＡ発現シグネチャー | |
| JP2011501949A (ja) | 特定の癌の診断及び予後診断 | |
| ES2724404T3 (es) | Un procedimiento basado en microARN para evaluar el pronóstico de un paciente de cáncer de próstata | |
| US20220267863A1 (en) | Compositions and methods for determining the prognosis of bladder urothelial cancer | |
| CN101878313A (zh) | 预测鳞状细胞肺癌的方法 | |
| US9068232B2 (en) | Gene expression signature for classification of kidney tumors | |
| CN104673883A (zh) | 用于预测早期非转移性结直肠癌预后的微rna生物标记物及检测方法 | |
| US9765334B2 (en) | Compositions and methods for prognosis of gastric cancer | |
| Khoshnevisan et al. | A significant upregulation of miR-886-5p in high grade and invasive bladder tumors | |
| CN102770561B (zh) | 用于诊断不同亚型肺癌的基于组织的微-rna方法 | |
| CN115125304B (zh) | 一种用于非小细胞肺癌早期诊断或检测的ceRNA调控网络及其应用 | |
| CN110139936A (zh) | 口腔癌、咽癌和喉癌的生物标记 | |
| US11021756B2 (en) | MiRNA markers for the diagnosis of osteosarcoma | |
| JP2024086170A (ja) | 分析方法、キット及び検出用デバイス | |
| WO2011039757A2 (en) | Compositions and methods for prognosis of renal cancer | |
| WO2010070637A2 (en) | Method for distinguishing between adrenal tumors | |
| CN104726454B (zh) | hsa‑miR‑1280在非小细胞肺癌中的作用及其应用 | |
| US20210147944A1 (en) | Methods for monitoring and treating prostate cancer | |
| KR20150108493A (ko) | 바이러스 인코딩된 마이크로 RNA hsv1-miR-H18 및 hsv2-miR-H9-5p의 전립선암에 대한 진단 용도 | |
| JP5884219B2 (ja) | ｍｉＲＮＡ発現プロファイリングに基づく尿路上皮癌の検出方法 | |
| WO2010018585A2 (en) | Compositions and methods for prognosis of melanoma | |
| CN104651363B (zh) | hsa‑miR‑1260b在非小细胞肺癌转移中的作用及其应用 |